Received Mar 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | xx9n4 | — |
Inappropriate age at vaccine administration; This non-serious case was reported by a consumer via call center representative and described the occurrence of inappropriate age at vaccine administration in a 66-year-old male patient who received MMR (Priorix) (batch number xx9n4) for prophylaxis. Concurrent medical conditions included diabetes (Diabetes). On 07-MAR-2025, the patient received the 1st dose of Priorix. On 07-MAR-2025, an unknown time after receiving Priorix, the patient experienced inappropriate age at vaccine administration (Verbatim: Inappropriate age at vaccine administration). The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 18-MAR-2025 The consumer was the reporter. The reporter stated that he received his first dose of Priorix on 07th March 2025 and the patient was 66 years old which led to inappropriate age at vaccine administration. The patient was born in and did not think he was vaccinated in his country. Due to increased cases of , in the where was resides, he was contacted by his pharmacy and advised he should be vaccinated. The patient was unable to provide the street address, zip code, phone number for the pharmacy. The patient stated that he has a diagnosis of Type 2 diabetes. No further information was obtained/provided.
Diabetes (Diabetes)